查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1867191

可待因市場依產品類型、劑型、用途、通路和最終用戶分類－2025-2032年全球預測

Codeine Market by Product Type, Form, Application, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，可待因市場規模將成長至 59.8 億美元，複合年成長率為 4.79%。

關鍵市場統計數據
基準年 2024 41.1億美元
預計年份：2025年 43.1億美元
預測年份 2032 59.8億美元
複合年成長率 (%) 4.79%

全面概述可待因療法，包括其臨床作用、監管複雜性、安全問題以及醫療保健領域相關人員不斷變化的期望

可待因在現代治療實務中佔有複雜而重要的地位，它既是一種長期使用的鎮痛和鎮咳藥物，也是監管機構和公共衛生政策的焦點。臨床上，可待因的藥理特性及其在組合藥物中的應用使其在包括疼痛管理和止咳在內的多種適應症中保持著重要作用。然而，其代謝特性和患者反應的個體差異意味著需要謹慎用藥。近年來，衛生部門和處方醫生越來越重視風險控制、患者選擇以及適合不同年齡層的製劑，尤其是在兒童和老年人群中。

深入分析受監管加強、治療替代、供應韌性以及處方趨勢等因素影響，正在重塑可待因市場格局的關鍵變化。

可待因市場正經歷多重變革，重塑臨床實務、供應鏈結構和監管因應措施。多個司法管轄區加強監管，提高了處方、標籤和上市後監測的標準，促使生產商和臨床醫生優先考慮風險管理措施和循證藥物管理方案。同時，治療替代療法和針對特定適應症的非鴉片類替代藥物的推廣，正在改變處方趨勢，並促使人們更加關注多模式疼痛管理方案以及在臨床適宜的情況下使用非鴉片類止咳藥。

評估2025年美國關稅對可待因供應鏈、原料藥採購成本、臨床應用和生產的累積影響

2025年美國關稅政策對全球可待因生態系統累積，促使企業調整籌資策略，揭露原料藥採購成本差異，並重新評估庫存和製造地。影響關鍵中間體和原料藥進口的關稅變化，促使製造商考慮近岸外包和供應商多元化，以此保障供應連續性，同時也提升了垂直整合生產能力的戰略價值。為此，採購部門正在擴展供應商資格認證流程，並加強對供應商績效的監控，以保護臨床用品免受暫時性貿易摩擦的影響。

細分市場分析揭示了不同產品類型、配方選擇、臨床應用、分銷管道和終端用戶環境的需求模式。

細分市場分析揭示了不同的需求促進因素和臨床要求如何轉化為差異化的產品開發和分銷策略。按產品類型分類，鹽酸可待因、磷酸可待因、硫酸可待因和復方製劑之間的差異決定了化學品採購途徑、製劑相容性和監管文件配置。複方製劑通常需要額外的動態和安全性驗證。按劑型分類，注射劑、糖漿和片劑之間的動態影響著臨床應用案例和供應鏈選擇。注射劑的需求受肌肉注射和靜脈注射兩個細分市場的影響，這兩個細分市場對無菌性和低溫運輸的要求不同。糖漿的選擇取決於含糖或無糖選項，這與患者群體和標籤要求有關。同時，片劑劑型必須平衡緩釋性和速釋特性，以滿足疼痛管理的需求。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 對非處方可待因銷售限制的收緊影響了市場進入和消費行為。
  • 新興市場對含低劑量可待因的止咳藥需求不斷成長
  • 公共衛生和政策舉措推動了向防濫用可待因製劑的過渡。
  • 開發一種數位處方監測工具，以防止可待因的濫用和轉移。
  • 全球供應鏈中斷對可待因原料供應和價格的影響
  • 受鴉片類藥物危機影響而進行的醫療改革可能會導致可待因處方行為的審查增加。
  • 減少可待因在輕度疼痛管理的偏好偏好非鴉片類止痛藥
  • 非專利藥可待因產品系列的擴大加劇了生產商之間的價格競爭。
  • 網路藥局和灰色市場通路的興起，助長了全球範圍內不受監管的可待因分銷。
  • 創新固定劑量可待因複方製劑療法，以因應病患依從性挑戰

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的可待因市場

  • 鹽酸可待因
  • 磷酸可待因
  • 硫酸可待因
  • 組合藥物

9. 按劑型分類的可待因市場

  • 注射
    • 肌肉內注射
    • 靜脈注射
  • 糖漿
    • 糖度
    • 無醣
  • 藥片
    • 緩釋性
    • 立即生效

第10章 按應用分類的可待因市場

  • 止咳藥
    • 成人配方
    • 兒科配方
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛

第11章 按分銷管道分類的可待因市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 依最終用戶分類的可待因市場

  • 診所
  • 居家醫療
  • 醫院

13. 各地區可待因市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的可待因市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國可待因市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Johnson & Johnson
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Sandoz International GmbH
    • GlaxoSmithKline plc
    • Aurobindo Pharma Limited
    • Cipla Limited
    • Dr. Reddy's Laboratories Limited
    • Sun Pharmaceutical Industries Limited
Product Code: MRR-99555D550530

The Codeine Market is projected to grow by USD 5.98 billion at a CAGR of 4.79% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.11 billion
Estimated Year [2025] USD 4.31 billion
Forecast Year [2032] USD 5.98 billion
CAGR (%) 4.79%

Comprehensive overview of codeine therapeutics, clinical roles, regulatory complexities, safety concerns, and evolving stakeholder expectations in healthcare

Codeine occupies a complex and consequential position within contemporary therapeutic practice, serving as both a long-established analgesic and antitussive agent and a focal point for regulatory scrutiny and public health policy. Clinically, codeine's pharmacologic profile and its inclusion in combination products have sustained its role across a range of pain management and cough suppression indications, while its metabolism and potential for variable patient response have driven careful stewardship in prescribing. Over recent years, health authorities and prescribers have intensified emphasis on risk mitigation, patient selection, and age-appropriate formulations, particularly where pediatric and elderly populations are concerned.

As a result, manufacturers, clinicians, and distributors operate in an environment where supply continuity, formulation innovation, and compliance with divergent national regulations converge. This environment demands a layered understanding of product variants, permissible formulations, and the interplay between clinical utility and safety obligations. Transitional technologies such as tele-prescribing, combined with evolving pharmacovigilance expectations, are changing how codeine products are accessed and monitored. Consequently, stakeholders must balance therapeutic access with robust mitigation of misuse and diversion risks while maintaining operational resilience across manufacturing and distribution channels.

In-depth review of major shifts reshaping the codeine landscape driven by regulatory tightening, therapeutic substitution, supply resilience and prescribing

The landscape for codeine is undergoing several transformative shifts that are redefining clinical practice, supply chain architecture, and regulatory engagement. Regulatory tightening in multiple jurisdictions has elevated the standards for prescribing, labeling, and post-market surveillance, prompting manufacturers and clinicians to prioritize risk management measures and evidence-based stewardship programs. Concurrently, therapeutic substitution and the expansion of non-opioid alternatives for specific indications have altered prescribing trajectories, encouraging greater emphasis on multimodal pain management pathways and non-opioid antitussives where clinically appropriate.

Supply chain resilience has become a strategic imperative as raw material controls, geopolitical tensions, and logistic bottlenecks expose vulnerabilities in active pharmaceutical ingredient sourcing and finished product distribution. At the same time, innovation in formulations-ranging from sugar-free syrups to extended-release tablets and combination products-reflects both patient-centric demands and regulatory accommodation for safer dosing. Digital tools for prescribing, adverse-event monitoring, and adherence support are gaining traction, aligning clinical decision-making with real-world safety data. Together, these shifts are creating a healthcare ecosystem in which manufacturers, payers, and providers must coordinate to ensure therapeutic access while meeting heightened expectations for safety, transparency, and supply continuity.

Evaluation of cumulative effects from United States tariff actions in 2025 on codeine supply chains, API sourcing costs, clinical access, and manufacturing

United States tariff actions implemented in 2025 have exerted a cumulative effect on the global codeine ecosystem by redirecting sourcing strategies, exposing cost differentials in active pharmaceutical ingredient procurement, and prompting reassessments of inventory and manufacturing footprints. Tariff changes affecting key intermediates and finished product imports have encouraged manufacturers to evaluate nearshoring and supplier diversification as mechanisms to protect supply continuity, while also increasing the strategic value of vertically integrated production capabilities. In response, procurement teams have expanded supplier qualification processes and intensified supplier performance monitoring to insulate clinical supply from episodic trade friction.

Clinicians and health systems have experienced indirect consequences through procurement cycles and formulary reviews, leading to an increased preference for products with stable supply chains and transparent provenance. Pharmaceutical manufacturers have accelerated conversations on domestic production capacity, contract manufacturing partnerships, and API substitution where scientific and regulatory frameworks permit. Regulatory authorities and trade policymakers have, in some cases, instituted exemptions or expedited review pathways for essential medicines to preserve clinical access, and private-sector actors have adopted hedging strategies in inventory management to mitigate near-term disruptions. The net effect is a recalibration of operational priorities where trade policy, clinical continuity, and production agility intersect.

Segmentation insights revealing demand patterns across product types, formulation options, clinical applications, distribution channels and end-user settings

Segmentation analysis reveals how heterogeneous demand drivers and clinical requirements translate into differentiated product development and distribution strategies. Based on product type, distinctions among Codeine Hydrochloride, Codeine Phosphate, Codeine Sulfate, and Combination Products determine chemical sourcing pathways, formulation compatibility, and regulatory dossier composition, with combination products often requiring additional pharmacodynamic and safety demonstration. Based on form, the dynamics between Injection, Syrup, and Tablet formats influence clinical use cases and supply chain choices; Injection demand is shaped by intramuscular and intravenous subsegments that impose distinct sterility and cold-chain requirements, Syrup offerings are influenced by sugar based and sugar free choices tied to patient populations and labeling expectations, while Tablet formats must balance extended release and immediate release profiles to meet analgesic regimens.

Based on application, differentiation between Cough Suppression and Pain Management carries implications for age segmentation and dosing strategies; cough suppression pathways further divide into adult formulations and pediatric formulations that require separate clinical and regulatory attention, and pain management splits into acute pain and chronic pain pathways that demand tailored benefit-risk assessments. Based on distribution channel, the roles of Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy affect inventory management, prescription validation, and patient counseling practices. Finally, based on end user, clinics, home care, and hospitals each present unique procurement behaviors and clinical governance frameworks that must be addressed through targeted commercial and clinical strategies to ensure appropriate access and oversight.

Regional comparative insights exposing regulatory variation, clinical access challenges, supply chain fragility, and demand trends guiding strategic priorities

Regional dynamics exert a persistent influence on how codeine products are regulated, supplied, and used in clinical practice, and variations by geography shape both short-term responses and long-term strategies. In the Americas, regulatory frameworks and healthcare delivery systems create a mix of centralized procurement and diverse prescribing practices, producing a landscape in which supplier reliability and distribution accountability are highly valued. In Europe, Middle East & Africa, fragmentation across regulatory regimes and heterogenous reimbursement environments combine with strong pharmacovigilance expectations to require regionally nuanced regulatory strategies and rigorous post-market monitoring. In Asia-Pacific, rapid expansion of healthcare infrastructure and varying degrees of local manufacturing capacity have produced both opportunities for domestic production and the need to harmonize quality standards to enable cross-border supply.

Across these regions, supply chain resilience, regulatory alignment, and clinical stewardship priorities diverge in emphasis but converge on shared objectives: preserving safe therapeutic access, ensuring traceable supply chains, and mitigating misuse. Strategic decisions regarding manufacturing footprint, regulatory submissions, and distribution partnerships must therefore be informed by region-specific constraints and enablers. Effective regional strategies incorporate local regulatory engagement, tailored clinical education initiatives, and commercially feasible logistics arrangements, enabling stakeholders to reconcile global product strategies with the operational realities of each geography.

Company insights into innovation strategies, portfolio diversification, manufacturing adaptability and partnerships shaping the competitive codeine landscape

Company-level dynamics in the codeine landscape reflect a balance between innovation, operational flexibility, and compliance with tightening regulatory requirements. Leading manufacturers and generic producers have prioritized portfolio diversification and formulation innovation to retain clinical relevance while addressing safety concerns and patient preferences. Strategic investments in sugar free syrup formulations, pediatric-appropriate dosing forms, and extended-release tablets demonstrate how product design can mitigate certain clinical risks and improve adherence across specific patient cohorts.

At the same time, manufacturing adaptability and supply chain transparency have emerged as core competitive differentiators. Companies that have invested in multi-sourced APIs, GMP-compliant facilities, and validated contract manufacturing partnerships are better positioned to navigate procurement disruptions and policy shifts. Commercial strategies increasingly emphasize collaborative relationships with healthcare systems, pharmacovigilance data sharing, and targeted clinical education to support appropriate use. Partnerships with contract research and manufacturing organizations enable faster scale-up and flexibility, while proprietary formulation know-how and robust quality systems sustain regulatory readiness and market access.

High-impact, pragmatic recommendations for industry leaders to balance patient access, regulatory compliance, supply security, and responsible opioid stewardship

To sustain therapeutic access while meeting heightened safety expectations and supply uncertainties, industry leaders should pursue a set of pragmatic, high-impact actions. Strengthening supplier networks and qualifying alternative API sources will reduce single-source risk and create room for agile manufacturing responses when trade policies or logistics issues arise. Concurrently, investing in formulation diversification-such as developing sugar free syrups, pediatric-friendly doses, and controlled-release tablets-aligns product offerings with evolving clinical guidance and patient needs. These investments should be coupled with enhanced pharmacovigilance systems and active collaboration with regulators to ensure labeling and usage guidance reflect best available evidence.

Commercially, organizations should prioritize transparent communication with healthcare providers and payers to build confidence in product quality and continuity. This includes targeted education programs on responsible prescribing, adverse-event reporting, and appropriate substitution where applicable. Operationally, leaders should consider capacity-building in contract manufacturing relationships and regional production hubs to buffer against external shocks. Finally, governance mechanisms that integrate compliance, clinical stewardship, and supply planning into executive decision-making will support balanced outcomes that preserve patient access while limiting misuse and diversion.

Methodology combining primary stakeholder interviews, regulatory review, clinical evidence synthesis, and multi-source validation to deliver actionable insights

The research underlying this analysis combines primary stakeholder engagement, regulatory review, clinical evidence synthesis, and rigorous multi-source validation to produce actionable findings. Primary inputs included structured interviews with clinicians, regulatory specialists, supply chain managers, and commercial leaders to capture operational realities and emergent practice patterns. Regulatory documents, clinical guidelines, and peer-reviewed literature were systematically reviewed to ground interpretation in current standards of care and safety expectations. Synthesis of these inputs enabled triangulation of clinical trends, formulation preferences, and distribution behaviors.

Data quality controls included cross-validation of interview findings against published guidance and manufacturing standards, and iterative expert feedback to refine interpretations and recommendations. Segmentation and regional analyses were constructed to align product, form, application, distribution, and end-user perspectives with geographic regulatory environments. The methodology prioritized transparency in assumptions and traceability of sources, enabling readers to follow the evidentiary basis for conclusions and to request tailored analyses aligned with specific commercial or operational questions.

Conclusion synthesizing clinical, regulatory, supply chain, and commercial imperatives that will shape near-term therapeutic use and stewardship priorities

In summary, the therapeutic and commercial trajectory for codeine products is shaped by intersecting forces: intensified regulatory scrutiny, evolving clinical alternatives, persistent supply chain vulnerabilities, and the need for prudent stewardship to minimize harm. These forces require integrated strategies that align product design, supply architecture, and clinician engagement to maintain safe access while reducing potential for misuse. As regulatory frameworks continue to evolve and trade dynamics exert influence on sourcing and pricing behavior, stakeholders who proactively adapt their manufacturing, procurement, and clinical support models will be best positioned to sustain reliable supply and clinical relevance.

Looking ahead, effective responses will combine investment in formulation and manufacturing flexibility with robust pharmacovigilance and targeted education for prescribers and patients. Embedding these approaches within corporate governance and regional operational plans will enable organizations to reconcile public health obligations with commercial viability. The imperative is clear: a coordinated, evidence-based approach that safeguards patient access while strengthening the resilience and accountability of the codeine supply chain will define success in the near term.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing regulatory restrictions on over-the-counter codeine sales impacting market access and consumer behavior
  • 5.2. Emerging market demand growth for low-dose codeine combination products in cough remedies
  • 5.3. Shift towards abuse-deterrent codeine formulations driven by public health and policy initiatives
  • 5.4. Development of digital prescription monitoring tools to prevent codeine misuse and diversion
  • 5.5. Impact of global supply chain disruptions on codeine raw material availability and pricing
  • 5.6. Growing scrutiny on codeine prescribing practices following opioid epidemic-driven healthcare reforms
  • 5.7. Consumer preference shift towards non-opioid analgesics reducing codeine usage in mild pain management
  • 5.8. Expansion of generic codeine product portfolios intensifying price competition among manufacturers
  • 5.9. Rise of online pharmacies and gray market channels facilitating unregulated codeine distribution worldwide
  • 5.10. Innovations in fixed-dose codeine combination therapies addressing patient adherence challenges

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Codeine Market, by Product Type

  • 8.1. Codeine Hydrochloride
  • 8.2. Codeine Phosphate
  • 8.3. Codeine Sulfate
  • 8.4. Combination Products

9. Codeine Market, by Form

  • 9.1. Injection
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
  • 9.2. Syrup
    • 9.2.1. Sugar Based
    • 9.2.2. Sugar Free
  • 9.3. Tablet
    • 9.3.1. Extended Release
    • 9.3.2. Immediate Release

10. Codeine Market, by Application

  • 10.1. Cough Suppression
    • 10.1.1. Adult Formulations
    • 10.1.2. Pediatric Formulations
  • 10.2. Pain Management
    • 10.2.1. Acute Pain
    • 10.2.2. Chronic Pain

11. Codeine Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Codeine Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Codeine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Codeine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Codeine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Johnson & Johnson
    • 16.3.2. Sanofi S.A.
    • 16.3.3. Teva Pharmaceutical Industries Ltd.
    • 16.3.4. Viatris Inc.
    • 16.3.5. Sandoz International GmbH
    • 16.3.6. GlaxoSmithKline plc
    • 16.3.7. Aurobindo Pharma Limited
    • 16.3.8. Cipla Limited
    • 16.3.9. Dr. Reddy's Laboratories Limited
    • 16.3.10. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CODEINE MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CODEINE MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CODEINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CODEINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CODEINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CODEINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CODEINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CODEINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CODEINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CODEINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CODEINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CODEINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CODEINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CODEINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CODEINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 338. ASIA-PACIFIC CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 341. ASIA-PACIFIC CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 342. ASIA-PACIFIC CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 343. ASIA-PACIFIC CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 344. ASIA-PACIFIC CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 345. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 346. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 347. ASIA-PACIFIC CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 348. ASIA-PACIFIC CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 349. ASIA-PACIFIC CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 350. ASIA-PACIFIC CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 351. ASIA-PACIFIC CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 352. ASIA-PACIFIC CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 353. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 354. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 355. ASEAN CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 356. ASEAN CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 357. ASEAN CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 358. ASEAN CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 359. ASEAN CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 360. ASEAN CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 361. ASEAN CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 362. ASEAN CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 363. ASEAN CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 364. ASEAN CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 365. ASEAN CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 366. ASEAN CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 367. ASEAN CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 368. ASEAN CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 369. ASEAN CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 370. ASEAN CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 371. ASEAN CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 372. ASEAN CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 373. ASEAN CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 374. ASEAN CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 375. ASEAN CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 376. ASEAN CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 377. GCC CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 378. GCC CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 379. GCC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 380. GCC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 381. GCC CODEINE